Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Oncomed Pharmaceuticals Inc patents (2016 archive)


Recent patent applications related to Oncomed Pharmaceuticals Inc. Oncomed Pharmaceuticals Inc is listed as an Agent/Assignee. Note: Oncomed Pharmaceuticals Inc may have other listings under different names/spellings. We're not affiliated with Oncomed Pharmaceuticals Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "O" | Oncomed Pharmaceuticals Inc-related inventors


Tigit-binding agents and uses thereof

Agents that specifically bind tigit are disclosed. The tigit-binding agents may include polypeptides, antibodies, and/or bispecific agents. ... Oncomed Pharmaceuticals Inc

Compositions and methods for diagnosing and treating cancer

An isolated antibody that specifically binds to an extracellular domain of human dll4 and affects growth of a tumor comprising cancer stem cells is described. Also described is a method of treating cancer comprising administering a therapeutically effective amount of an anti-dll4 antibody.. ... Oncomed Pharmaceuticals Inc

Polynucleotides encoding vegf/dll4 binding agents

The present invention relates to vegf-binding agents, dll4-binding agents, vegf/dll4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human vegf, antibodies that specifically bind human dll4, and bispecific antibodies that specifically bind human vegf and/or human dll4. ... Oncomed Pharmaceuticals Inc

Methods and monitoring of treatment with a wnt pathway inhibitor

Methods for treating diseases such as cancer comprising administering a wnt pathway inhibitor, either alone or in combination with other anti-cancer agents, and monitoring for skeletal-related side effects and/or toxicity.. . ... Oncomed Pharmaceuticals Inc

Immunotherapy with binding agents

Binding agents that modulate the immune response are disclosed. The binding agents may include soluble receptors, polypeptides, and/or antibodies. ... Oncomed Pharmaceuticals Inc

Methods and monitoring of treatment with a dll4 antagonist

Methods for treating diseases such as cancer comprising administering a dll4 antagonist, either alone or in combination with other anti-cancer agents, and monitoring for cardiovascular side effects and/or toxicity.. . ... Oncomed Pharmaceuticals Inc

Frizzled-binding agents and uses thereof

Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. ... Oncomed Pharmaceuticals Inc

Methods for treating cancer with dll4 antagonists

The present invention provides methods for treating cancer. More particularly, the invention provides methods for treating cancer comprising administrating doses of a dll4 antagonist.. ... Oncomed Pharmaceuticals Inc

Met-binding agents and uses thereof

The present invention relates to binding agents that specifically bind human met, binding agents that specifically bind one or more components of the wnt pathway, bispecific agents that bind both human met and one or more components of the wnt pathway, and methods of using the agents for treating diseases such as cancer.. . ... Oncomed Pharmaceuticals Inc

Identification of predictive biomarkers associated with wnt pathway inhibitors

The present invention provides biomarkers for identifying tumors likely to respond to treatment with wnt pathway inhibitors. Also provided are methods for identifying tumors and/or patients that are likely to be responsive or non-responsive to treatment with a wnt pathway inhibitor. ... Oncomed Pharmaceuticals Inc

Method for making heteromultimeric molecules

Methods for making heteromultimeric molecules, such as bispecific antibodies, and compositions comprising these molecules are disclosed. The methods include introducing mutations in amino acids that are in contact at the interface of two polypeptides, such that the electrostatic interaction between the ion pairs is altered.. ... Oncomed Pharmaceuticals Inc

Tnfrsf-binding agents and uses thereof

Polypeptides and agents that bind a tnf receptor superfamily protein are disclosed, particularly agents that specifically bind gitr, ox40, or cd40. The polypeptides or agents may include fusion polypeptides, particularly polypeptides comprising gitrl, ox40l, or cd40l and/or bispecific agents. ... Oncomed Pharmaceuticals Inc

Methods for treating cancers comprising k-ras mutations

Methods of inhibiting tumor growth, methods of treating cancer, and methods of reducing the frequency of cancer stem cells in a tumor are described. Particularly, the methods are directed to tumors or cancers that comprise a k-ras mutation. ... Oncomed Pharmaceuticals Inc

Methods of treating neuroendocrine tumors using frizzled-binding agents

Novel methods of treating neuroendocrine tumors are provided. In one embodiment, the method comprises administering to a subject in need thereof a therapeutically effective dose of a wnt antagonist. ... Oncomed Pharmaceuticals Inc

06/16/16 / #20160166684

Treatment of fibrotic diseases

The present invention relates to rspo and lgr antagonists, and methods of using the rspo and lgr antagonists for treating or preventing fibrotic diseases.. . ... Oncomed Pharmaceuticals Inc

05/19/16 / #20160137744

Met-binding agents and uses thereof

The present invention relates to binding agents that specifically bind human met, binding agents that specifically bind one or more components of the wnt pathway, bispecific agents that bind both human met and one or more components of the wnt pathway, and methods of using the agents for treating diseases such as cancer.. . ... Oncomed Pharmaceuticals Inc

03/24/16 / #20160082079

Wnt antagonist and methods of treatment and screening

The present invention relates to compositions comprising wnt antagonists and methods of treating wnt-associated diseases and disorders, such as cancer, inducing differentiation, and reducing the frequency of cancer stem cells, as well as novel methods of screening for such wnt antagonists. In particular, the invention discloses soluble fzd, sfrp and ror receptors and their use.. ... Oncomed Pharmaceuticals Inc

02/25/16 / #20160053016

Compositions and methods for diagnosing and treating cancer

The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. ... Oncomed Pharmaceuticals Inc

02/04/16 / #20160030561

Methods of treating pancreatic cancer

Novel methods of treating pancreatic cancer are provided. In one embodiment, the method comprises determining notch mrna expression levels in pancreatic cancer cells. ... Oncomed Pharmaceuticals Inc

01/07/16 / #20160002344

Rspo binding agents and uses thereof

The present invention relates to rspo-binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human rspo proteins and modulate β-catenin activity. ... Oncomed Pharmaceuticals Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Oncomed Pharmaceuticals Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Oncomed Pharmaceuticals Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###